- Conditions
- Hemophilia a, Hemophilia B
- Interventions
- SerpinPC
- Drug
- Lead sponsor
- ApcinteX Ltd
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–32
of 32
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia B, Hemophilia B, Moderately Severe or Severe
- Interventions
- BE-101
- Drug
- Lead sponsor
- Be Biopharma
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Davis, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 2 more
- Conditions
- Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A
- Interventions
- Emicizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 2 more
- Conditions
- Hemophilia A
- Interventions
- efanesoctocog alfa
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
- Conditions
- Hemophilia A
- Interventions
- Emicizumab, FVIII
- Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 6 Years to 19 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Palo Alto, California • San Diego, California + 7 more
- Conditions
- Hemophilia A
- Interventions
- SPK-8011QQ
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- Orange, California • San Francisco, California • Vallejo, California
- Conditions
- Hemophilia B
- Interventions
- REGV131, LNP1265
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older · Male only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2047
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 10 more
- Conditions
- Hemophilia A
- Interventions
- Recombinant Protein-Free Factor VIII (rAHF-PFM)
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more